PepGen Inc(PEPG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:38 PM ET (Korea 10/31 06:38)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.31 | Insider Own | 10.77% | Shs Outstand | 69.3M | Perf Week | -6.35% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | -2.14% | Insider Trans | -0.02% | Shs Float | 61.8M | Perf Month | 6.79% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.27 | Inst Own | 71.85% | Short Float | 6.16% | Perf Quarter | 25.53% |
| Income | -0.07B | P/S | - | EPS this Y | 48.91% | Inst Trans | -5.16% | Short Ratio | 4.09 | Perf Half Y | 34.86% |
| Sales | 0.00B | P/B | 1.37 | EPS next 5Y | 21.56% | ROA | -59.06% | Short Interest | 3.80M | Perf YTD | -63.75% |
| Book/sh | 1.73 | P/C | 1.39 | EPS past 3/5Y | 10.01% -63.43% | ROE | -75.45% | 52W High | -69.74% ($7.80) | Perf Year | -47.9% |
| Cash/sh | 1.69 | P/FCF | - | Sales past 3/5Y | - | ROIC | -54.34% | 52W Low | 80.15% ($1.31) | Perf 3Y | -57.93% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 56% | Gross Margin | - | Volatility(W/M) | 8.99% 8.55% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.36 | EPS Q/Q | 63.49% | Profit Margin | - | RSI (14) | 42.01 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.36 | Sales Q/Q | - | SMA20 | -6.37% ($2.52) | Beta | 2.01 | Target Price | $10.19 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/6 | SMA50 | -14.31% ($2.75) | Rel Volume | 1.2 | Prev Close | $2.41 |
| Employees | 56 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 8.61% - | SMA200 | -22.22% ($3.03) | Avg Volume(3M) | 0.93M | Price | $2.36 |
| IPO | 2022/5/6 | Option/Short | Yes/Yes | Trades | 5118 | Volume | 1,121,098 | Change | -2.07% |
🧬 PepGen is a US clinical-stage biotech company developing oligonucleotide-based therapeutics that target serious neuromuscular and neurological rare diseases. The company is focused on leveraging its proprietary cell-penetrating peptide delivery platform to improve drug delivery efficiency into muscle and the central nervous system, and it remains concentrated on pipeline research and development without any commercialized products yet.
Over the past 1 year, on the lower side
70% below its 1-year high.
Traded about as much as usual. That is 120% of its average volume.
PEPG has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.9% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -57.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 71.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #319 of 595 in the industry
Based on market cap of $163M.
FAQ
What kind of company is PEPG?
PEPG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PEPG?
The market cap of PEPG is approximately $163M, ranking 4,157 within its sector.
What is the 52-week high and low for PEPG?
PEPG has recorded a 52-week high of $7.80 and a low of $1.31.
